Predicate |
Object |
assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_fd7810eae8c1d9cf9b4968987f37060c |
classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-39558 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-517 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-4375 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-50 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-5011 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-505 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-713 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-6893 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-57492 |
classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-4375 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-50 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K45-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-713 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-517 |
filingDate |
2017-02-16-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_95a23d31ad633b862fa074524fdcea25 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_0db6c87ee4729f46c0ba2fc3efddbe9d http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_7ce854080cd724f5b9e95cfaed66ebb2 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_8c65c6154815be30023aada2cf8a3f8e http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_101ad40afd3aefc1b2ab0c7fbe1030eb |
publicationDate |
2017-08-24-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
publicationNumber |
WO-2017140793-A1 |
titleOfInvention |
Modulators of ccr9 for treating tumor resistance to immune responses |
abstract |
The present invention pertains to novel modulators of tumor resistance against T-cell mediated cytotoxic immune responses. The invention provides antagonists of tumor immune escape mechanisms and methods and other aspects related thereto, and therefore provides novel approaches for treating or aiding a treatment of various cancerous diseases and/or the diagnosis thereof. The invention specifically discloses C-C chemokine receptor type 9 (CCR9) as a checkpoint molecule in tumor resistance against cytotoxic T-cells. Provided is the inhibition of CCR9 expression, CCR9 signalling and/or CCR9-T-Cell interaction and inhibitors or antagonists thereof. In particular aspects, the invention provides combination therapeutics and/or therapies involving such inhibitors or antagonists. The invention furthermore provides screening methods for novel cancer therapeutics modulating CCR9 action, diagnostic approaches to detect cancer resistance to cytotoxic T-cells as well as pharmaceutical compositions and diagnostic kits for performing, for use with or related to these methods. |
isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-114502204-A |
priorityDate |
2016-02-16-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
type |
http://data.epo.org/linked-data/def/patent/Publication |